Literature DB >> 23049094

Educating our students about pharmaceutical care for those living with cancer.

Claire Anderson1, David M Plevin, Ross A McKinnon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23049094      PMCID： PMC3448457          DOI： 10.5688/ajpe767119

Source DB:  PubMed          Journal:  Am J Pharm Educ        ISSN： 0002-9459            Impact factor:   2.047


× No keyword cloud information.
  11 in total

Review 1.  Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing?

Authors:  Margaret von Mehren; Nicolas Widmer
Journal:  Cancer Treat Rev       Date:  2010-11-24       Impact factor: 12.111

2.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.

Authors:  Carlo Gambacorti-Passerini; Laura Antolini; François-Xavier Mahon; Francois Guilhot; Michael Deininger; Carmen Fava; Arnon Nagler; Chiara Maria Della Casa; Enrica Morra; Elisabetta Abruzzese; Anna D'Emilio; Fabio Stagno; Philipp le Coutre; Rafael Hurtado-Monroy; Valeria Santini; Bruno Martino; Fabrizio Pane; Andrea Piccin; Pilar Giraldo; Sarit Assouline; Muheez A Durosinmi; Onno Leeksma; Enrico Maria Pogliani; Miriam Puttini; Eunjung Jang; Josy Reiffers; Maria Grazia Valsecchi; Dong-Wook Kim
Journal:  J Natl Cancer Inst       Date:  2011-03-21       Impact factor: 13.506

Review 3.  Adherence to medication.

Authors:  Lars Osterberg; Terrence Blaschke
Journal:  N Engl J Med       Date:  2005-08-04       Impact factor: 91.245

4.  Disease progression in some cancers may be due to low blood levels of targeted therapies.

Authors:  Rabiya S Tuma
Journal:  J Natl Cancer Inst       Date:  2008-06-24       Impact factor: 13.506

Review 5.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

6.  Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.

Authors:  Allan Hackshaw; Michael Roughton; Sharon Forsyth; Kathryn Monson; Krystyna Reczko; Richard Sainsbury; Michael Baum
Journal:  J Clin Oncol       Date:  2011-03-21       Impact factor: 44.544

7.  Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.

Authors:  Ann H Partridge; Philip S Wang; Eric P Winer; Jerry Avorn
Journal:  J Clin Oncol       Date:  2003-02-15       Impact factor: 44.544

8.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

9.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

10.  Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

Authors:  Lucien Noens; Marie-Anne van Lierde; Robrecht De Bock; Gregor Verhoef; Pierre Zachée; Zwi Berneman; Philippe Martiat; Philippe Mineur; Koen Van Eygen; Karen MacDonald; Sabina De Geest; Tara Albrecht; Ivo Abraham
Journal:  Blood       Date:  2009-04-06       Impact factor: 22.113
View more
  5 in total

1.  Practice of pharmacy and language competency: delivery of integrated cross-cultural care.

Authors:  Katayoon Ahmadi; Keivan Ahmadi; Syed Imran
Journal:  Am J Pharm Educ       Date:  2013-08-12       Impact factor: 2.047

2.  Comment on "Educating our students about pharmaceutical care for those living with cancer".

Authors:  Michael D Newton; Terry L Schwinghammer; Myke R Green
Journal:  Am J Pharm Educ       Date:  2012-11-12       Impact factor: 2.047

3.  A Team-based Assignment to Integrate Basic Science and Pharmacotherapeutic Principles for Anticancer Agents.

Authors:  Sonali Kurup; Paiboon Jungsuwadee; Prashant Sakharkar
Journal:  Am J Pharm Educ       Date:  2017-06       Impact factor: 2.047

4.  An oncology pharmacy practice elective course for third-year pharmacy students.

Authors:  Kelly K Nystrom; Amy M Pick
Journal:  Am J Pharm Educ       Date:  2013-02-12       Impact factor: 2.047

5.  Care of cancer patients with liver and bone metastases - the place of pharmaceutical care in a balanced plan, focused on the patient's needs and goals.

Authors:  Katarzyna A Rygiel; Mariola Drozd; Lucyna Bułaś
Journal:  Arch Med Sci       Date:  2016-06-13       Impact factor: 3.318
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.